Cynosure Lutronic bolsters its strength in APAC -- The world's fastest-growing medical aesthetics device region, with dual regulatory approvals for the Clarity II™ in China and Japan, February 2026
 |
SINGAPORE, Feb. 27, 2026 /PRNewswire/ --Cynosure Lutronic,a global leader in energy-based medical aestheticdevices, announcedtodaythat Clarity II, its dual-wavelength long-pulse laser platform, has received regulatory approval in China and Japan. Thismarksa significant expansion of the company's clinically approved laser portfolio across two of Asia's most highly regulated aestheticmarkets.
Clarity II Receives Regulatory Clearance in China and Japan
"The approval enables the introduction of a single, integrated dual wavelength laser platform designed to support multiple treatment indications and diverse patient profiles and is also reflective ofCynosure Lutronic's growing strength across the Asia Pacific region" said Nadav Tomer, CEO of Cynosure Lutronic.
China: Regulatory Approval
InChina, Clarity II (marketed asCLARITY II ICD) has received regulatory approval for use in medicalinstitutionsas of 12thFebruary 2026.
- Product Name:Clarity IIICD
- Approved Indications:
- 755nm laser – approved to reduce wrinkles on the cheeks
- 1064nmlaser – approved to reduce unwanted bodyhair
The approval authorizes the use of a single integrated platform across multiple treatment applications within regulated clinical settingsofChina.
Japan: Regulatory Approval
InJapan, Clarity II has received regulatory clearance as of9th January 2026for use in medical aesthetic practices.
- Product Name:Clarity II
- Approved Indication:
- Alexandrite 755nm /Nd:YAG1064nm approved forLong-term hair reduction
The clearance confirms compliance with Japan's stringent medical device regulatory requirements for laser-based aesthetic treatments.
ClarityII is a dual-wavelength long-pulse laser system designed to support a range of aesthetic medical applications
Clinical and Operational Context
In both China and Japan,medicalaestheticpracticesareoperatingunder increasingly rigorous regulatory and clinical expectations, with heightened emphasis on treatment precision, indication-specific use, and safety.
The regulatory approvals of Clarity II reflect growing demand for laser platforms thatconsolidatemultipleclinically validatedapplications within a single system, whilemaintainingstrict control over energy delivery and treatment parameters. In China, approval across both hair removal and wrinkle treatment applications enables practitioners to address multiplepatientneedswithone versatile platform. In Japan, clearance of the latest-generation system reinforces confidence in technological refinement and output consistency within a highly regulated clinical environment.
Together, these approvals position Clarity II as a platform aligned with the evolving standards of advanced aesthetic practice in Asiacompliance, and clinical versatility are increasingly critical.
Clarity II delivers precision and efficiency through advanced dual-wavelength technology
About Clarity II
Clarity II is a dual-wavelength long-pulse laser system designed to support a range of aesthetic medical applications. The platform integrates:
- Alexandrite 755nm andNd:YAG1064nm wavelengths in a single system
- Large spot sizes to support efficient treatment of broad areas
- Short pulse duration capabilities for refined and precision-based treatments
- A fiber-free system architecture designed to simplify operation and maintenance
- Automated delivery features intended to support consistency and practitioner workflow
About CynosureLutronic
CynosureLutronicwas formed following the merger of Cynosure andLutronicin 2024whichcreatesa global medical aesthetics organization built on more than 60 years of combined innovation in energy-based technologies.
CynosureLutronicdevelops and commercializes energy-based devices across a wide range of aesthetic indicationswith direct operations in North America, Europe, and Asia-Pacific, and product distribution in approximately 130 countries.
